# Amgen Inc.  Share Price Target ‘$307.59’, now 6.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/amgen-inc.share-price-target-307.59-now-6.9-upside-potential/4121142869
- Published: 2024-02-16T11:17:18+00:00
- Author: Charlotte Edwards

**Amgen Inc.** with ticker code (AMGN) now have 22 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The range between the high target
price and low target price is between $380.00 and $170.00 calculating the average
target share price we see $307.59. (at the time of writing). Given that the stocks
previous close was at $287.82 this would indicate that there is a potential upside
of 6.9%. There is a 50 day moving average of $295.22 while the 200 day moving average
is $260.38. The market capitalization for the company is 154.92B. The current share
price for the company is: $289.07 USD

 The potential market cap would be $165,559,242,596 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 23.14, revenue per share of $52.69
and a 10.32% return on assets.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures
and delivers various human therapeutics. It operates in human therapeutics segment.
The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab),
Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha(
evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb),
Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO(
blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (
adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene
laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras,
Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment
of serious illness in the areas of inflammation, oncology/hematology, bone health,
cardiovascular disease, nephrology and neuroscience.

Share on:
